Clinical Trial Update: Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of brivanib alaninate in persistent or recurrent cervical cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Adenocarcinoma
• Cervical Adenosquamous Carcinoma
• Cervical Cancer
• Cervical Carcinoma
• Cervical Squamous Cell Carcinoma Not Otherwise Specified
• Persistent Disease

Drugs mentioned

• Brivanib alaninate (brivanib alaninate)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-01-04